Collard J
Acta Psychiatr Belg. 1979 Nov-Dec;79(6):686-703.
Forty patients with some "social maladjustments" or disturbed interpersonal relationship under 2 mg pimozide (Orap: a 24 h long-acting neuroleptic) for six to twelve months. Concomitant but complementary medication was kept unchanged. Control was based on: long-term investigation (1/2 - 1 year), quantification, use of two scales. Statistical evaluation of the changes in "cardinal symptoms" showed a significant improvement in tension, disorders of sleep, intellectual disturbances, cardiovascular symptoms and gastrointestinal complaints. More detailed analysis of the other 27-item rating scale revealed a dramatic improvement in anxiety and paranoidism. The overall appreciation shows that: 25 patients responded well or very well to pimozide, eight did moderately, seven poorly. Neurasthenia and related states with predominant asthenia turned out to be no indication for pimozide treatment. Except for some cases of increased fatigue, tolerance was exceptionally good. The trial showed that extra patience is required from the therapist as a clinical onset of one to two months is not uncommon.
40例存在某些“社会适应不良”或人际关系紊乱的患者,服用2毫克匹莫齐特(奥哌咪嗪:一种长效抗精神病药),疗程6至12个月。同时使用的辅助药物保持不变。对照基于:长期调查(半年至1年)、量化、使用两种量表。对“主要症状”变化的统计评估显示,紧张、睡眠障碍、智力障碍、心血管症状和胃肠道不适有显著改善。对另一个27项评定量表的更详细分析显示,焦虑和偏执有显著改善。总体评估表明:25例患者对匹莫齐特反应良好或非常良好,8例反应中等,7例反应较差。以虚弱为主的神经衰弱及相关状态并非匹莫齐特治疗的适应证。除了一些疲劳加重的病例外,耐受性非常好。试验表明,由于一到两个月的临床起效并不罕见,治疗师需要格外耐心。